Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Mark Licari joins CereVasc, LLC as Vice President of Operations, Deep Manufacturing Experience Added to the Team

Posted on: 04 Apr 18
Mark Licari joins CereVasc, LLC as Vice President of Operations, Deep Manufacturing Experience Added to the Team

PR Newswire

BOSTON, April 4, 2018

BOSTON, April 4, 2018 /PRNewswire/ -- CereVasc, LLC, a company focused on improving the care of patients with communicating hydrocephalus announced today the addition of Mark Licari to the senior management team of CereVasc, LLC.  Mr. Licari, a very successful manufacturing operations professional, brings years of experience to CereVasc from previous positions with Cytyc Corporation as Vice President of Worldwide Service & Technical Operations, Constitution Medical as Vice President of Program Management and most recently as Vice President of Operations, Drug Delivery Systems at Insulet Corporation.

"We are delighted to have Mark join our team.  I have worked along side Mark for more than 20 years and his drive and attention to detail are a perfect match for our stage of development as we move the eShunt System™ into manufacturing.  Mark's immediate mission is to manage that transition to manufacturing in anticipation of the first human use of the eShunt System™ planned for later this year," said Dan Levangie, President & C.E.O. of CereVasc, LLC.

"While it's still early in the development of this technology, we believe we have the potential to transform the treatment of patients who deal with the shortcomings of our current, 60-year-old open surgical approach and Mark is an important addition to our very focused team," Mr. Levangie continued.

About CereVasc, LLC

CereVasc, LLC is a medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases.  Their first product, the eShunt System™ is an endovascular cerebrospinal fluid (CSF) shunt and associated delivery componentry designed to avoid the need for invasive surgery, general anesthesia and hospitalization associated with the current surgical treatment of communicating hydrocephalus using ventriculo-peritoneal shunts.

View original content:


PR Newswire

Last updated on: 04/04/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.